[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100447598":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":10,"locations":23,"responsibleParty":44,"collaborators":10,"id":46,"slug":10,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":10,"eligibilityCriteria":51,"healthyVolunteers":47,"sex":52,"minAge":10,"maxAge":10,"enrollmentInfo":53,"targetDuration":10,"studyType":56,"phases":10,"briefSummary":57,"conditions":58,"keywords":10,"overallStatus":26,"whyStopped":10,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":70},{"fullName":5,"class":6},"M.D. Anderson Cancer Center","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Observational (medical records review)",null,"Patients' medical records are reviewed.",[13],"Other: Electronic Health Record Review",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"Electronic Health Record Review","Medical records are reviewed",[9],[20],{"name":21,"affiliation":5,"role":22},"Nicolas L Palaskas","PRINCIPAL_INVESTIGATOR",[24],{"facility":25,"status":26,"city":27,"state":28,"zip":29,"country":30,"cosmosGeoPoint":31,"geoPoint":36,"contacts":37},"M D Anderson Cancer Center","RECRUITING","Houston","Texas","77030","United States",{"type":32,"coordinates":33},"Point",[34,35],-95.36327,29.76328,{"lat":35,"lon":34},[38,43],{"name":39,"role":40,"phone":41,"phoneExt":10,"email":42},"Nicolas L. Palaskas","CONTACT","713-563-3532","nlpalaskas@mdanderson.org",{"name":39,"role":22,"phone":10,"phoneExt":10,"email":10},{"type":45,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100447598",false,"NCT05108519","Complications and Clinical Response in Cancer Patients Treated With Anti-VEGF-Related Therapies","A Prospective Study Evaluating Complications and Clinical Response in Cancer Patients Treated With Anti-VEGF-Related Therapies","Inclusion Criteria:\n\n* Patients must be able to understand and be willing to sign a written informed consent document\n* Patients must be receiving any anti-VEGF-related regimen in monotherapy or combination therapy","ALL",{"count":54,"type":55},170,"ESTIMATED","OBSERVATIONAL","This study collects information about complications and clinical response in cancer patients treated with anti-VEGF-related therapies. This study aims to observe side effects that may happen to patients with advanced cancer who are treated with anti-VEGF related therapy. This may help doctors learn if there are any relationships between these side effects and how the disease may respond to treatment.",[59,60],"Hematopoietic and Lymphoid Cell Neoplasm","Malignant Solid Neoplasm","2026-02-17",{"date":63,"type":64},"2026-02-19","ACTUAL",{"date":66,"type":64},"2019-04-08",{"date":68,"type":55},"2027-02-02",{"name":5,"class":6},1]